Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Genta, Inc. (NasdaqNM:GNTA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
2 Oak Way
Berkeley Heights, NJ 07922
Phone: (908) 286-3980
Fax: (908) 464-1701
Employees (last reported count): 32
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 56%
·Over the last 6 months:
 · 3 insider buys; 3,000  shares
·Institutional: 47% (107% of float)
(94 institutions)
·Net Inst. Buying: 3.74M shares (+12.72%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Genta, Inc. is a biopharmaceutical company whose research efforts are focused on the development of new biopharmaceutical products for the treatment of patients with cancer. The Company's research portfolio is currently divided into four areas including the Antisense Program, which involves the administration of synthetic oligonucleotides that are complementary to specific mRNA transcripts; the Gallium Products Franchise, which is a bone-seeking element that exerts potent effects on the skeletal system; Androgenics Compounds, which are products comprised of a portfolio of small molecules that are useful for the treatment of prostate cancer; and Decoy Aptamers, which employ oligonucleotides to bind to specific proteins known as transcription factors.
More from Market Guide: Expanded Business Description

Financial Summary
GNTA is a biopharmaceutical company that focuses its research on the development of new products for the treatment of patients with cancer. For the six months ended 6/30/01, revenues totaled $82 thousand, up from $0. Net loss applicable to Common increased 21% to $18.4 million. Revenues reflect the inclusion of licence revenues. Net loss reflects an increase in payroll and marketing expenses and the inclusion of a $1 million Promega settlement charge.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Pay

Raymond Warrell, Jr., M.D., 50
Chairman, Pres, CEO
$142K
Michael Weiss, 34
Vice Chairman
--  
Alfred Fernandez
CFO, Exec. VP
--  
Loretta Itri
Exec. VP, Clinical R&D, CMO
--  
Bruce Williams
Sr. VP of Sales and Marketing
--  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:GNTAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$4.719
Recent Price$10.46 
52-Week High
on 14-June-2001
$13.98 
Beta1.35 
Daily Volume (3-month avg)647.4K
Daily Volume (10-day avg)623.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+14.6%
52-Week Change
relative to S&P500
+53.8%
Share-Related Items
Market Capitalization$570.3M
Shares Outstanding54.5M
Float24.0M
Dividends & Splits
Annual Dividendnone 
Last Split: 1 for 10 on 7-Apr-1997
Per-Share Data
Book Value (mrq)$0.72 
Earnings (ttm)-$0.37 
Earnings (mrq)-$0.21 
Sales (ttm)$0.00 
Cash (mrq)$0.70 
Valuation Ratios
Price/Book (mrq)14.49 
Price/EarningsN/A 
Price/Sales (ttm)4,967.29 
Income Statements
Sales (ttm)$104.0K
EBITDA (ttm)-$24.8M
Income available to common (ttm)-$19.1M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-48.98%
Return on Equity (ttm)-53.43%
Financial Strength
Current Ratio (mrq)8.06 
Debt/Equity (mrq)0 
Total Cash (mrq)$37.6M
Short Interest
As of 8-Aug-2001
Shares Short3.91M
Percent of Float16.3%
Shares Short
(Prior Month)
4.20M
Short Ratio9.69 
Daily Volume404.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.